Apr 03, 2008, 01.36 PM IST | Source:

Ranbaxy launches BONISTA- Teriparatide injection

Ranbaxy launches BONISTA- Teriparatide injection for the treatment of osteoporosis in India in collaboration with Virchow Biotech Pvt Ltd, Hyderabad, India.

Ranbaxy Laboratories Limited (Ranbaxy) today announced the launch of BONISTA- Teriparatide injection (recombinant human parathyroid hormone) for the treatment of Osteoporosis in collaboration with Virchow Biotech Pvt Ltd , Hyderabad, India. Ranbaxy is the first company to launch this bio-generic product in the world.


The product has been indigenously researched at Virchow Biotech and developed with aid from the Department of Science and Technology, Government of India.


Commenting on the launch of the product, Mr. Sanjeev I. Dani, Senior Vice President & Regional Director (Asia & CIS), Ranbaxy, said, “With growing longevity, Osteoporosis- a condition characterised by loss of bone mass, would gain increased attention. Ranbaxy has a number of new products in its pipeline including ‘Bonista’, for the Osteoporosis patients who are normally treated by orthopaedics and gynaecologists. Bonista is also a classic example of our endeavours to offer quality biogeneric therapeutic options to doctors and an affordable and efficacious product  to  patients.”


The Osteoporosis segment in India currently has a market size of around Rs. 219 crores and  grew more than 29% in value terms in 2006-07.


Osteoporosis is highly prevalent in India. An estimated 61 million people in India are reported to be affected by it. The life span of an average Indian has increased and this contributes to the increased incidence of osteoporosis. Recent data indicates  that Indians have lower bone density than their North American and European counterparts. One of the reasons could be that  the  majority of Indians have low vitamin D status and are on low dietary calcium which makes them prone to bone diseases As regards the burden of osteoporosis in the Indian scenario, 50% women have osteoporosis and   this translates to over 30 million in actual numbers.


Although data on the prevalence of osteoporotic fractures  is  limited, it is estimated that each year, osteoporosis causes more than 1.5 million fractures, resulting in permanent disability, loss of independence, and death. 


Sourced From: Ranbaxy Laboratories Ltd

Ranbaxy Labs stock price

On March 27, 2015, Ranbaxy Laboratories closed at Rs 807.05, down Rs 11.95, or 1.46 percent. The 52-week high of the share was Rs 844.00 and the 52-week low was Rs 344.00.

The latest book value of the company is Rs 25.79 per share. At current value, the price-to-book value of the company was 31.29.

Set email alert for


video of the day

Budget 2015-16: Revive capex through savings on cheap crude says Kotak Sec

Explore Moneycontrol

Copyright © Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of is prohibited.